Supplementary Table 5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Autor: Zena Werb, Howard Y. Chang, Joe W. Gray, Colin C. Collins, Colleen A. Sweeney, Hope S. Rugo, Paul Yaswen, Gerrit J.P. Dijkgraaf, Mark D. Sternlicht, Qing Xue, Devon A. Lawson, Kun Qu, James E. Korkola, Obi L. Griffith, Sheryl R. Krig, Jonathan Chou, Guiqing Huang, Hosein Kouros-Mehr, Adam S. Adler, Laurie E. Littlepage
Rok vydání: 2023
DOI: 10.1158/2159-8290.22528947.v1
Popis: PDF file - 37K, Drug list identified in silico. List of drugs identified in silico to inhibit breast cancer cell lines that overexpress ZNF217. Correlation of ZNF217 expression in the cell line panel with the drug panel of ~50,000 drugs generated by the NCI Developmental Therapeutics Program (dtp.nci.nih.gov) identified several drugs that selectively inhibited growth of cells, assessed by GI50, expressing high levels of ZNF217 with a low drug concentration
Databáze: OpenAIRE